Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 296

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Study on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II

Study on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II

Study on Pre-Operative Nivolumab and Relatlimab for Adults with Stage II-IIIa Muscle-Invasive Bladder Cancer

Study on Pre-Operative Nivolumab and Relatlimab for Adults with Stage II-IIIa Muscle-Invasive Bladder Cancer

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Study of Brentuximab Vedotin, Adriamycin, Vinblastine, and Dacarbazine for Children with Advanced Stage Hodgkin Lymphoma